{
  "drug_name": "Cefazolin",
  "tradename": "Ancef, Kefzol",
  "drug_shortage": [
    {
      "preparation": "Injection",
      "start_date": "2018-06-04",
      "notes": ""
    }
  ],
  "usage_and_dosing": {
    "general": [
      "Cefazolin, FDA-approved in 1973, is a first-generation parenteral cephalosporin with a wide variety of uses for infections caused by susceptible gram-positive cocci, e.g., MSSA (not MRSA or enterococci), E. coli, P. mirabilis, and Klebsiella sp.",
      "Rare failures of cefazolin therapy of MSSA bacteremia due to bacterial hyperproduction of type A beta-lactamase (Antimicrob Agents Chemother 2010;54:2206; Antimicrob Agents Chemother 2009;53:3437).",
      "Major use is for surgical prophylaxis.",
      "Antistaphylococcal penicillins have historically been preferred for CNS infection due to concern about poor blood-brain penetration of cefazolin. Recent studies have called this belief into question (Pharmacotherapy 2023;43:85; Open Forum Infect Dis 2021;9:ofab649; Clin Microbiol Infect 2020;26:1415.e1)."
    ],
    "adult_dose": {
      "usual_dose": "1-2 gm IV/IM q8h (max 12 gm/day)",
      "surgical_prophylaxis": "2 gm IV within 60 min prior to skin incision. Repeat dose in 4 hrs if surgery is prolonged"
    },
    "pediatric_dose": {
      "dose_age_gt_28_days": "50-150 mg/kg/day (divided q6-8h)",
      "max_day": "6 gm"
    }
  },
  "renal_adjustment": {
    "half_life_normal": "2",
    "half_life_esrd": "40-70",
    "dose_renal_function_normal": "1-2 gm IV q8h",
    "crcl_or_egfr": "CrCl >50: No dosage adjustment. CrCl 10-50: 0.5-2 gm q8-12h. CrCl <10: 0.5-1 gm q24h",
    "hemodialysis": "0.5-1 gm q24h (AD on dialysis days). Outpatients: 2 gm AD MW, 3 gm AD Fri 52",
    "capd": "0.5 gm q12h",
    "crrt": "1-2 gm q12h",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "No dosage adjustment"
  },
  "other_adjustment": [
    "ECMO: See ECMO Drug Dosing Adjustment.",
    "Obesity: Obesity Dosing Adjustments."
  ],
  "adverse_effects": [
    "Hypersensitivity (rash, anaphylaxis [rare])",
    "Cefazolin does not share the same R-1 or R-2 side chain with any other beta-lactam.",
    "See Drug Allergy: Penicillins, Cephalosporins, Overview.",
    "GI (diarrhea, C. difficile colitis)",
    "Fever",
    "Local phlebitis",
    "Hematologic: positive Coombs, eosinophilia, neutropenia, thrombocytopenia"
  ],
  "pregnancy_risk": {
    "fda_risk_category": "No evidence of toxicity in humans or animals",
    "lactation": "Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "preferred": [
      "Staphylococcus aureus, methicillin-sensitive (MSSA)",
      "Staphylococcus epidermidis, methicillin-susceptible (MSSE)",
      "Staphylococcus lugdunensis",
      "Staphylococcus saprophyticus",
      "Staphylococcus sp., coagulase-negative (Methicillin susceptible); S. hominis, S. capitis, others"
    ],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "T>MIC",
    "preparations": "Injection",
    "food_recommendation": null,
    "oral_absorption_percent": null,
    "tmax_hr": null,
    "peak_serum_conc_ug_ml": "188 (1 gm IV, SD)",
    "peak_urine_conc_ug_ml": ">1000 (500 mg IM, SD) 27",
    "protein_binding_percent": "73-87",
    "volume_of_distribution_vd_l_kg": "0.19 L/kg",
    "avg_serum_half_life_hr": "2",
    "elimination": "Renal",
    "bile_penetration_percent": "29-300",
    "csf_blood_percent": "6.7 (median AUC ratio) 26",
    "therapeutic_levels_in_csf": "Possibly",
    "auc_ug_hr_ml": "236 (1 gm IV, 0-inf)"
  },
  "enzyme_transporter_mediated_interactions": {
      "cyp450s_substrate": [],
      "transporters_substrate": ["OAT1", "OAT3"],
      "ugts_substrate": [],
      "cyp450s_inhibited": [],
      "transporters_inhibited": [],
      "ugts_inhibited": [],
      "cyp450s_induced": [],
      "transporters_induced": [],
      "ugts_induced": [],
      "impact_on_serum_drug_concentrations": "None expected"
  },
  "major_drug_interactions": [
    "No significant interactions"
  ]
}
